Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

261.83USD
23 Apr 2018
Change (% chg)

$-1.19 (-0.45%)
Prev Close
$263.02
Open
$263.14
Day's High
$264.27
Day's Low
$260.57
Volume
255,145
Avg. Vol
586,319
52-wk High
$370.53
52-wk Low
$244.31

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 30.95 32.74
EPS (TTM): 15.23 -- --
ROI: 17.59 14.84 14.38
ROE: 28.64 16.34 16.07

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

20 Apr 2018

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

20 Apr 2018

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

20 Apr 2018

Biogen to pay $1 billion to Ionis in new partnership

April 20 Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

20 Apr 2018

Samsung C&T mulling raising up to $2.8 bln to buy stake in biopharma affiliate: MBC

SEOUL Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.

09 Apr 2018

Samsung C&T mulling raising up to $2.8 bln to buy stake in biopharma affiliate - MBC

SEOUL, April 9 Samsung C&T Corp, de facto holding company of Samsung Group, is considering raising up to 3 trillion won ($2.8 billion) to buy a 30 percent stake in sub-subsidiary Samsung Bioepis Co Ltd, a South Korean TV channel reported on Monday.

09 Apr 2018

AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023

April 5 AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023.

05 Apr 2018

BRIEF-Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar

* BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDI™ (ADALIMUMAB BIOSIMILAR) IN EUROPE

05 Apr 2018

Biogen to buy Pfizer's neurology drug in deal nearing $600 million

Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for a symptom associated with schizophrenia in a deal that could near $600 million and mark its foray into the emerging market for neuropsychiatry.

12 Mar 2018

UPDATE 1-Biogen to buy Pfizer's neurology drug in deal nearing $600 mln

March 12 Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for a symptom associated with schizophrenia in a deal that could near $600 million and mark its foray into the emerging market for neuropsychiatry.

12 Mar 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.72 +0.06
Pfizer Inc. (PFE.N) $36.76 +0.12
Novartis AG (NOVN.S) CHF76.04 -0.04
Merck & Co., Inc. (MRK.N) $60.16 +1.33
Roche Holding Ltd. (ROG.S) CHF217.60 +1.95
Roche Holding Ltd. (RO.S) CHF221.40 +1.40
Bayer AG (BAYGn.DE) €98.79 -0.21
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.71 +0.43
GlaxoSmithKline plc (GSK.L) 1,445.00 +15.00

Earnings vs. Estimates